Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.

Mohlin S, Hansson K, Radke K, Martinez S, Blanco-Apiricio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O'Neill M, Pastor J, von Stedingk K, Bexell D.

EMBO Mol Med. 2019 Aug;11(8):e10058. doi: 10.15252/emmm.201810058. Epub 2019 Jul 16.

2.

Multidimensional intratumour heterogeneity in neuroblastoma.

von Stedingk K, Gisselsson D, Bexell D.

Oncotarget. 2019 Jan 1;10(1):3-5. doi: 10.18632/oncotarget.26524. eCollection 2019 Jan 1. No abstract available.

3.

Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma.

Braekeveldt N, von Stedingk K, Fransson S, Martinez-Monleon A, Lindgren D, Axelson H, Levander F, Willforss J, Hansson K, Øra I, Backman T, Börjesson A, Beckman S, Esfandyari J, Berbegall AP, Noguera R, Karlsson J, Koster J, Martinsson T, Gisselsson D, Påhlman S, Bexell D.

Cancer Res. 2018 Oct 15;78(20):5958-5969. doi: 10.1158/0008-5472.CAN-18-0527. Epub 2018 Aug 28.

4.

Promoter-associated proteins of EPAS1 identified by enChIP-MS - A putative role of HDX as a negative regulator.

Hamidian A, Vaapil M, von Stedingk K, Fujita T, Persson CU, Eriksson P, Veerla S, De Preter K, Speleman F, Fujii H, Påhlman S, Mohlin S.

Biochem Biophys Res Commun. 2018 May 5;499(2):291-298. doi: 10.1016/j.bbrc.2018.03.150. Epub 2018 Mar 26.

PMID:
29577908
5.

Refined control of cell stemness allowed animal evolution in the oxic realm.

Hammarlund EU, von Stedingk K, Påhlman S.

Nat Ecol Evol. 2018 Feb;2(2):220-228. doi: 10.1038/s41559-017-0410-5. Epub 2018 Jan 18. Review.

PMID:
29348641
6.

Predominance of girls with cancer in families with multiple childhood cancer cases.

Stjernfelt KJ, von Stedingk K, Wiebe T, Hjorth L, Olsson H, Øra I.

BMC Cancer. 2017 Dec 19;17(1):868. doi: 10.1186/s12885-017-3899-8.

7.

No reason to reconsider HIF-2 as an oncogene in neuroblastoma and other cancer forms.

Mohlin S, von Stedingk K, Pietras A, Påhlman S.

Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10856-E10858. doi: 10.1073/pnas.1716644115. Epub 2017 Dec 12. No abstract available.

8.

Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum.

Persson CU, von Stedingk K, Bexell D, Merselius M, Braekeveldt N, Gisselsson D, Arsenian-Henriksson M, Påhlman S, Wigerup C.

Sci Rep. 2017 Aug 31;7(1):10274. doi: 10.1038/s41598-017-09662-8.

9.

The RNA-binding protein HuR inhibits expression of CCL5 and limits recruitment of macrophages into tumors.

Brauß TF, Winslow S, Lampe S, Scholz A, Weigert A, Dehne N, von Stedingk K, Schmid T, Brüne B.

Mol Carcinog. 2017 Dec;56(12):2620-2629. doi: 10.1002/mc.22706. Epub 2017 Jul 28.

PMID:
28731284
10.

Musculocontractural Ehlers-Danlos syndrome and neurocristopathies: dermatan sulfate is required for Xenopus neural crest cells to migrate and adhere to fibronectin.

Gouignard N, Maccarana M, Strate I, von Stedingk K, Malmström A, Pera EM.

Dis Model Mech. 2016 Jun 1;9(6):607-20. doi: 10.1242/dmm.024661. Epub 2016 Apr 21.

11.

PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.

Mohlin S, Hamidian A, von Stedingk K, Bridges E, Wigerup C, Bexell D, Påhlman S.

Cancer Res. 2015 Nov 1;75(21):4617-28. doi: 10.1158/0008-5472.CAN-15-0708. Epub 2015 Oct 2.

12.

Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients.

Bergenfelz C, Larsson AM, von Stedingk K, Gruvberger-Saal S, Aaltonen K, Jansson S, Jernström H, Janols H, Wullt M, Bredberg A, Rydén L, Leandersson K.

PLoS One. 2015 May 20;10(5):e0127028. doi: 10.1371/journal.pone.0127028. eCollection 2015.

13.

Differential regulation of HIF-1α and HIF-2α in neuroblastoma: Estrogen-related receptor alpha (ERRα) regulates HIF2A transcription and correlates to poor outcome.

Hamidian A, von Stedingk K, Munksgaard Thorén M, Mohlin S, Påhlman S.

Biochem Biophys Res Commun. 2015 Jun 5;461(3):560-7. doi: 10.1016/j.bbrc.2015.04.083. Epub 2015 Apr 23.

14.

Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.

von Stedingk K, De Preter K, Vandesompele J, Noguera R, Øra I, Koster J, Versteeg R, Påhlman S, Lindgren D, Axelson H.

Int J Cancer. 2015 Aug 15;137(4):868-77. doi: 10.1002/ijc.29461. Epub 2015 Feb 20.

15.

The HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interaction.

Newie I, Søkilde R, Persson H, Grabau D, Rego N, Kvist A, von Stedingk K, Axelson H, Borg Å, Vallon-Christersson J, Rovira C.

PLoS One. 2014 May 14;9(5):e97200. doi: 10.1371/journal.pone.0097200. eCollection 2014.

16.

snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis.

von Stedingk K, Koster J, Piqueras M, Noguera R, Navarro S, Påhlman S, Versteeg R, Ora I, Gisselsson D, Lindgren D, Axelson H.

Transl Oncol. 2013 Aug 1;6(4):447-57. Print 2013 Aug.

17.

Tumors with nonfunctional retinoblastoma protein are killed by reduced γ-tubulin levels.

Ehlén Å, Rosselló CA, von Stedingk K, Höög G, Nilsson E, Pettersson HM, Jirström K, Alvarado-Kristensson M.

J Biol Chem. 2012 May 18;287(21):17241-7. doi: 10.1074/jbc.M112.357038. Epub 2012 Apr 6.

18.

Nuclear localization of γ-tubulin affects E2F transcriptional activity and S-phase progression.

Höög G, Zarrizi R, von Stedingk K, Jonsson K, Alvarado-Kristensson M.

FASEB J. 2011 Nov;25(11):3815-27. doi: 10.1096/fj.11-187484. Epub 2011 Jul 25.

19.

JAG2 induction in hypoxic tumor cells alters Notch signaling and enhances endothelial cell tube formation.

Pietras A, von Stedingk K, Lindgren D, Påhlman S, Axelson H.

Mol Cancer Res. 2011 May;9(5):626-36. doi: 10.1158/1541-7786.MCR-10-0508. Epub 2011 Mar 14.

20.

The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma.

Mestdagh P, Boström AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, von Stedingk K, Ghesquière B, Schulte S, Dews M, Thomas-Tikhonenko A, Schulte JH, Zollo M, Schramm A, Gevaert K, Axelson H, Speleman F, Vandesompele J.

Mol Cell. 2010 Dec 10;40(5):762-73. doi: 10.1016/j.molcel.2010.11.038.

Supplemental Content

Loading ...
Support Center